Header Logo

Connection

Laurel Habel to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Laurel Habel has written about Breast Neoplasms.
Laurel Habel
Connection Strength
11.337
Breast Neoplasms
  1. Examination of fully automated mammographic density measures using LIBRA and breast cancer risk in a cohort of 21,000 non-Hispanic white women. Breast Cancer Res. 2023 08 06; 25(1):92.
    View in: PubMed
    Score: 0.515
  2. Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk. Nat Commun. 2020 10 09; 11(1):5116.
    View in: PubMed
    Score: 0.424
  3. Re: Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2020 02 01; 112(2):214-215.
    View in: PubMed
    Score: 0.404
  4. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
    View in: PubMed
    Score: 0.403
  5. Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives. Cancer Res. 2017 12 01; 77(23):6770-6776.
    View in: PubMed
    Score: 0.348
  6. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 02; 167(3):751-759.
    View in: PubMed
    Score: 0.345
  7. The Effect of California's Breast Density Notification Legislation on Breast Cancer Screening. J Prim Care Community Health. 2017 Apr; 8(2):55-62.
    View in: PubMed
    Score: 0.323
  8. Case-control study of mammographic density and breast cancer risk using processed digital mammograms. Breast Cancer Res. 2016 05 21; 18(1):53.
    View in: PubMed
    Score: 0.313
  9. Association between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort. Cancer Causes Control. 2015 Mar; 26(3):431-42.
    View in: PubMed
    Score: 0.285
  10. Reply to L. Cabel et al. J Clin Oncol. 2015 Jan 20; 33(3):292-3.
    View in: PubMed
    Score: 0.283
  11. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10; 32(20):2151-8.
    View in: PubMed
    Score: 0.273
  12. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
    View in: PubMed
    Score: 0.262
  13. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.253
  14. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013 Mar 14; 15(2):R24.
    View in: PubMed
    Score: 0.251
  15. Metabolic syndrome and mammographic density: the Study of Women's Health Across the Nation. Int J Cancer. 2011 Oct 01; 129(7):1699-707.
    View in: PubMed
    Score: 0.218
  16. Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2488-95.
    View in: PubMed
    Score: 0.212
  17. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010 Oct 01; 28(28):4300-6.
    View in: PubMed
    Score: 0.209
  18. Physical activity and change in mammographic density: the Study of Women's Health Across the Nation. Am J Epidemiol. 2010 May 01; 171(9):960-8.
    View in: PubMed
    Score: 0.204
  19. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.200
  20. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.199
  21. Pharmaceuticals that cause mammary gland tumors in animals: findings in women. Breast Cancer Res Treat. 2009 Jul; 116(1):187-94.
    View in: PubMed
    Score: 0.182
  22. Physical activity and mammographic density in a cohort of midlife women. Med Sci Sports Exerc. 2008 Mar; 40(3):451-6.
    View in: PubMed
    Score: 0.177
  23. Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). Breast Cancer Res Treat. 2008 Nov; 112(1):165-74.
    View in: PubMed
    Score: 0.174
  24. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
    View in: PubMed
    Score: 0.171
  25. Antibiotics and breast cancer. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1323.
    View in: PubMed
    Score: 0.168
  26. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2102-6.
    View in: PubMed
    Score: 0.161
  27. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25.
    View in: PubMed
    Score: 0.157
  28. Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat. 2006 Mar; 96(2):123-9.
    View in: PubMed
    Score: 0.154
  29. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72.
    View in: PubMed
    Score: 0.140
  30. Mammographic density mediates the protective effect of early-life body size on breast cancer risk. Nat Commun. 2024 May 13; 15(1):4021.
    View in: PubMed
    Score: 0.136
  31. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study. Radiology. 2023 06; 307(5):e222733.
    View in: PubMed
    Score: 0.127
  32. Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. J Am Coll Surg. 2023 07 01; 237(1):13-23.
    View in: PubMed
    Score: 0.126
  33. MiXcan: a framework for cell-type-aware transcriptome-wide association studies with an application to breast cancer. Nat Commun. 2023 Jan 23; 14(1):377.
    View in: PubMed
    Score: 0.124
  34. Anti-Müllerian hormone levels and breast cancer risk in the study of women's health across the nation. Cancer Causes Control. 2022 Aug; 33(8):1039-1046.
    View in: PubMed
    Score: 0.119
  35. Telehealth for Preoperative Evaluation of Patients With Breast Cancer During the COVID-19 Pandemic. Perm J. 2022 06 29; 26(2):54-63.
    View in: PubMed
    Score: 0.119
  36. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Res. 2022 04 12; 24(1):27.
    View in: PubMed
    Score: 0.118
  37. Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat. 2022 May; 193(1):225-235.
    View in: PubMed
    Score: 0.117
  38. Alcohol and Tobacco Use in Relation to Mammographic Density in 23,456 Women. Cancer Epidemiol Biomarkers Prev. 2020 05; 29(5):1039-1048.
    View in: PubMed
    Score: 0.101
  39. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998 Aug; 7(8):689-96.
    View in: PubMed
    Score: 0.091
  40. Feasibility of collecting tumor samples of breast cancer patients diagnosed up to 50 years ago in the Child Health and Development Studies. J Dev Orig Health Dis. 2017 Jun; 8(3):331-336.
    View in: PubMed
    Score: 0.083
  41. Oncologist and organizational factors associated with variation in breast cancer multigene testing. Breast Cancer Res Treat. 2017 May; 163(1):167-176.
    View in: PubMed
    Score: 0.082
  42. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg. 1997 Jan; 225(1):69-75.
    View in: PubMed
    Score: 0.082
  43. Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Res. 2016 09 15; 76(18):5415-22.
    View in: PubMed
    Score: 0.079
  44. Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol. 1996 Jul 15; 144(2):161-4.
    View in: PubMed
    Score: 0.079
  45. Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol. 2016 08 10; 34(23):2743-9.
    View in: PubMed
    Score: 0.078
  46. Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care. 2016 05 01; 22(5):e153-60.
    View in: PubMed
    Score: 0.078
  47. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
    View in: PubMed
    Score: 0.077
  48. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9.
    View in: PubMed
    Score: 0.077
  49. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.076
  50. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.073
  51. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.073
  52. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015 Apr 14; 15:278.
    View in: PubMed
    Score: 0.072
  53. A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
    View in: PubMed
    Score: 0.072
  54. Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health. 2015 May; 105(5):938-46.
    View in: PubMed
    Score: 0.072
  55. Occupation and breast cancer risk in middle-aged women. J Occup Environ Med. 1995 Mar; 37(3):349-56.
    View in: PubMed
    Score: 0.072
  56. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 2014 Nov; 21(12):3766-73.
    View in: PubMed
    Score: 0.068
  57. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care. 2014 May; 52(5):e30-8.
    View in: PubMed
    Score: 0.068
  58. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014 Apr; 144(3):689-99.
    View in: PubMed
    Score: 0.067
  59. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
    View in: PubMed
    Score: 0.067
  60. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
    View in: PubMed
    Score: 0.067
  61. Hormone receptors and breast cancer. Epidemiol Rev. 1993; 15(1):209-19.
    View in: PubMed
    Score: 0.062
  62. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):365-73.
    View in: PubMed
    Score: 0.062
  63. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan; 137(1):247-60.
    View in: PubMed
    Score: 0.061
  64. Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012 Nov; 18(11):704-12.
    View in: PubMed
    Score: 0.061
  65. Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat. 2012 Nov; 136(2):521-33.
    View in: PubMed
    Score: 0.061
  66. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
    View in: PubMed
    Score: 0.060
  67. Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt). 2012 Sep; 21(9):950-8.
    View in: PubMed
    Score: 0.060
  68. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.059
  69. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):673-80.
    View in: PubMed
    Score: 0.058
  70. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
    View in: PubMed
    Score: 0.057
  71. Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control. 2011 Oct; 22(10):1415-24.
    View in: PubMed
    Score: 0.056
  72. Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2011 Nov; 130(1):195-205.
    View in: PubMed
    Score: 0.055
  73. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011 Sep; 129(2):549-56.
    View in: PubMed
    Score: 0.055
  74. Norepinephrine antagonists and cancer risk. Int J Cancer. 2011 Feb 01; 128(3):737-8; author reply 739.
    View in: PubMed
    Score: 0.054
  75. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2479-87.
    View in: PubMed
    Score: 0.052
  76. Active, but not passive cigarette smoking was inversely associated with mammographic density. Cancer Causes Control. 2010 Feb; 21(2):301-11.
    View in: PubMed
    Score: 0.051
  77. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
    View in: PubMed
    Score: 0.048
  78. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 Apr 16; 100(8):597-8; author reply 599.
    View in: PubMed
    Score: 0.045
  79. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008 Jun; 109(3):573-9.
    View in: PubMed
    Score: 0.042
  80. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007 Aug; 18(6):613-20.
    View in: PubMed
    Score: 0.042
  81. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat. 2006 Sep; 99(1):47-57.
    View in: PubMed
    Score: 0.039
  82. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995 Jul 12; 274(2):137-42.
    View in: PubMed
    Score: 0.018
  83. Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. Breast Cancer Res. 2009; 11(4):R51.
    View in: PubMed
    Score: 0.012
  84. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008 Apr 16; 100(8):563-71.
    View in: PubMed
    Score: 0.011
  85. The association between mammographic breast density and bone mineral density in the study of women's health across the nation. Ann Epidemiol. 2007 Aug; 17(8):575-83.
    View in: PubMed
    Score: 0.010

© 2024 Kaiser Permanente